HOLLYWOOD, Fla.--(BUSINESS WIRE)--Ed Quilty, former CEO and Chairman of the Board of Derma Sciences Inc., has been named to the Board of Directors of bioactive wound care company SanMelix Laboratories, Hollywood, Florida.
Quilty became the sixth board member of SanMelix, a leader in bioactive advanced wound care dressings focusing on the unique medicinal properties of Buckwheat Honey for wound healing. As CEO and Chairman of the Board for Derma Sciences, Quilty led the publicly-held corporation’s U.S. distribution of MediHoney®, the first manuka honey dressing to receive FDA clearance for advanced wound care in the U.S.
“Ed Quilty is among--if not THE--most knowledgeable individual in the advanced wound care honey space in the U.S.,” said Diana Sabacinski, CEO of SanMelix. “His expertise, contacts and broad reaching relationships within the wound care community will help accelerate SanMelix’s growth and propel our success. We are delighted to have Ed join our team and assist us in meeting our revenue and business goals.”
Founded by Harvard-trained surgeon Dr. Kenneth A. Sabacinski, who has been involved in medical and surgical treatment of limb-threatening and chronic wounds for over 30 years, SanMelix is partially funded by 1,700 investors via StartEngine equity crowdfunding. A new campaign is currently underway, providing investment opportunities for those interested in contributing to its mission, which is faster and healthier healing.
The company’s first product, BEECure® R, is available on Amazon and Walmart.com. BEECure® M and BEECure® BH, advanced wound care dressings, are presently undergoing FDA regulatory submission.
Under Mr. Quilty’s direction and leadership, Derma Sciences Inc. grew from under $5 million in sales of its products for advanced wound care with less than 10 employees to become a leader in its industry with revenues of approximately $100 million and over 250 employees.
As an advisor for SanMelix, Quilty will engage Key Opinion Leaders and wound care companies to form strategic partnerships to advance the introduction and sales of SanMelix’s products.
Ed Quilty served as a board member as well as CEO to three other publicly traded healthcare companies and has led and managed numerous M&A transactions and financings with a total value of over $2 billion.